EMA Tackles How To Substantiate New Active Substance Claims For Biologics & ATMPs

 
• By Neena Brizmohun

The European Medicines Agency is seeking feedback on its position on assessing whether biological substances and advanced therapy medicinal products qualify for NAS status.

Gene therapies are among the products addressed in the new paper on NAS status • Source: Shutterstock

More from Europe

More from Geography